Cantor Fitzgerald Reiterates a Buy Rating on Elevance Health (ELV), Keeps the PT

​Elevance Health, Inc. (NYSE:ELV) is one of the Most Undervalued Long Term Stocks to Buy Right Now. On October 21, Sarah James from Cantor Fitzgerald reiterated a Buy rating on Elevance Health, Inc. (NYSE:ELV) with a price target of $400.

​The firm maintains a cautious outlook on the 2026 Medicaid Environment, noting that the company has conservative elements in its 2026 earnings per share projections. In addition, the firm also believes that execution in Medicare Advantage, commercial business, and Carelon to be critical for the company’s performance in 2026 and 2027. They believe this is particularly important due to the Medicaid visibility becoming increasingly uncertain.

​Despite the cautious outlook, Cantor Fitzgerald believes that Elevance Health, Inc. (NYSE:ELV) will outperform expectations in the Medicare Advantage and Carelon segments.

​Elevance Health, Inc. (NYSE:ELV) is a health insurer in the United States offering various health plans and services.

While we acknowledge the potential of ELV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.